PSA questions Flashcards
(175 cards)
Hyperkalaemia stages
Mild
Moderate
Severe
Mild 5.5-5.9 mmol/L
Moderate 6-6.4 mmol/L
Severe > 6.5 mmol/L
Emergency treatment for hyperkalaemia?
If severe ie >6.5 mmol/L or ECG changes- tall T waves, loss of P waves, broad QRS
Iv calcium gluconate- to stabilise myocardium
Insulin dextrose infusion- shifts K+ from ECF to ICF
Nebulised salbutamol
Extra: stop drugs e.g. ACEi
treat cause
Lower total K+: calcium resonium, loop diuretics, dialysis
1st line mx in T2DM
Metformin
Metformin giving patient GI side effects, change to what?
Modified release metformin
Metformin MOA?
Inhibits hepatic gluconeogenesis
Inhibits glucagon function
When would you add a SGLT-2 inhibitor to metformin in 1st line treatment?
If patient has
- high risk (QRISK >10%) or established CVD
- chronic HF
If metformin is contraindicated
(Also as a 2nd line option if Hba1c >58 despite 1st line)
If metformin is contraindicated, what would you give as a first line tx for T2DM?
If CI due to CVD or HF, give SGLT-2 inhibitor
Otherwise 1 of:
- DPP-4 inhibitor (gliptans)
- pioglitazone
- sulfonylurea e.g. glicazide
- SGLT-2 inhibitor e.g. dapaglifozin
When would you start a 2nd line medication in T2DM?
If Hba1c is >58mmol/mol despite 1st line
What would you give as 2nd line tx for T2DM?
Metformin + (one of below)
- DPP-4 inhibitor (gliptans)
- pioglitazone
- sulfonylurea
- SGLT-2 inhibitor
What would you give as 3rd line treatment for T2DM?
Add another of 2nd line options
E.g metformin + DPP-4 inhibitor + sulfonylurea
Or
Insulin therapy
MOA of metformin?
Inhibits hepatic gluconeogenesis
Inhibits glucagon function
MOA of SGLT-2 inhibitors?
And contraindication?
Reduced glucose reabsorption in kidneys
—> more excreted in urine
SGLT-2 is the main transport protein of glucose (90%)
CI: severe renal failure
Examples of SGLT-2 inhibitors? (4)
SGLT-2 abbreviated from?
Dapaglifozin
Canaglifozin
Empaglifozin
Ertuglifozin
Sodium glucose Co-transporter-2
DPP-4 inhibitor MOA?
Inhibits DPP-4 enzyme, an enzyme that destroys the hormone incretin. Incretin:
- encourages insulin release from b cells
- inhibits release of glucagon from a cells
So, less DPP-4 enzyme —> more incretin —> more insulin and less glucagon —> less glucose in blood
Side effects and contraindications of GPP-4 inhibitors?
SEs: GI problems
CIs: pancreatitis hx, hypoglycaemia, angioedema
Examples of DPP-4 inhibitors?
Sitagliptin
Vildagliptin
Alogliptin
Lingagliptin
Main thiazolidinedione used?
Pioglitazone
MOA of pioglitazone
A thiazolidinedione
Binds to receptors in adipocytes —> promotes adipogenesis and fatty acid uptake —> reduces circulating fatty acid conc —> improves insulin sensitivity
But, can therefore lead to weight gain
MOA of sulfonylureas?
Directly stimulate B cells to release insulin
Therefore can only be used if there is some B cell function I.e should not be used in type 1 diabetes
Examples of sulfonylurea? (4)
Glicazide
Glipizide
Glimepiride
Tolbutamide
MOA of GLP-1 receptor agonist?
Stimulates release of insulin from B cells
GLP-1 = glucagon like peptide
Examples of GLP-1 receptor agonists?
Liraglutide
Lixisenatide
Dulaglutide
Semaglutide
All injections, some OD, some once weekly. Should only be commenced by a specialist
‘GL’ “glutides”
When are GLP-1 mimetic (receptor agonist) indicated
If control not achieved or tolerated (Hba1c >58 mmol/mol) on triple therapy.
Used if
- BMI over 35
- insulin therapy not concordant with lifestyle
*only continue if Hba1c reduces by 11 mmol/mol AND body weight decreases by 8%
Normal Na range?
135-145 mmol/L